

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|-----------------------|-------------------|------------------|
| In re: | Cadilla <i>et al.</i> | Confirmation No.: | 3786 |
| Serial No.: | 10/505,333 | Filing Date: | August 23, 2004 |
| Patent No.: | 7,319,104 B2 | Issue Date: | January 15, 2008 |
| Title: | HPPARS ACTIVATORS | | |

**Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

**REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR §1.322**

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 CFR §1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith.

The Commissioner is authorized to charge any fees or to credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Robert H. Brink
Robert H. Brink
Attorney for Patentee
Registration No. 36,094

Date: 15 May 2008
Customer No. 26347
GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: (919) 483-3323
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,319,104 B2

Page 1 of 1

APPLICATION NO. : 10/505,333

ISSUE DATE : January 15, 2008

INVENTOR(S) : Cadilla *et al.*

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

Claim 4 (Column 204, Line 36) should read as follows:

-- 4. A compound according to claim 2 wherein R⁴ and R⁵ are --

Claim 8 (Column 204, Line 46) should read as follows:

-- 8. A compound according to claim 5 wherein R⁷ and R⁸ are --

Claim 14 (Column 205, Lines 56-58) should read as follows:

-- 2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid; --

Claim 14 (Column 206, Lines 1-9) should read as follows:

-- [2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]acetic acid;
2-[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;
2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)-2-propylphenoxy]-2-methylpropanoic acid; --

Claim 16 (Column 206, Line 65) should read as follows:

-- 16. A compound according to claim 1 wherein R¹ and --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GLAXOSMITHKLINE

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.